DARA Biosciences (NASDAQ: DARA) is expecting to hear soon on the status of its Orphan Drug application submitted to The Food and Drug Administration (FDA) in November of last year for its drug KRN5500, which is being studied for the…
Author: Scott Matusow
Trade Alert: Bought $DARA – Price Target opinion = $1.35 – $1.45
More DD to come, for reference, please see http://seekingalpha.com/article/1156481-imminent-catalysts-should-keep-investor-interest-alive-for-dara-biosciences?source=yahoo http://seekingalpha.com/article/1042311-dara-the-future-of-oncology-biopharma-on-the-cheap?source=yahoo http://seekingalpha.com/article/866781-time-to-buy-dara-bio The above chart shows me a cup and handle almost complete. I like the last 3 candles. As those of you know who listen to my show, I…
Additional DD on Pozen: PA8140
The low dose version of PA32540 is called PA8140. PA8140 is not listed in their pipeline or on their website — from company’s latest 10Q: The FDA indicated that it will make a final determination during the NDA review. Based on…
4 Small Cap Biopharmas With Near-Term Catalysts
To begin this week, I list four biopharma companies I feel have significant catalysts coming up. According to investinganswers.com a catalyst is defined as news or information that changes a pricing trend in a security. Catalysts can drive an investment…
Pozen: An Undervalued Investment And Catalyst Trade Opportunity
Small cap biopharmas that make for good long term investments are hard to find. Most small cap biopharmas burn a ton of cash while developming treatments for a variety of ailments and rare diseases. Today, we focus on Pozen (NASDAQ:POZN)…
UPDATE: closed position $IMUC: price target opinion same = $2.60 – $2.80 Catalyst = interim data + bullish chart
UPDATED 2/6/13: Closed position at $2.75 today as trade hit upper end of my top target of $2.80, will watch this one closely for a possible re-entry. ImmunoCellular expects that the trial’s data safety monitoring committee will conduct an…
The Obesity Epidemic – EnteroMedics New Treatment Approach
Our focus turns to EnteroMedics (NASDAQ:ETRM), which offers a new treatment approach currently in Phase III clinical trials, designed to help morbidly obese people lose weight. EnteroMedics’ approach may be a better solution for people who see little or no…
UPDATED: EnteroMedics (ETRM) Basic DD and Thesis
EnteroMedics Inc. (ETRM) I bought a nice amount of shares. Catalyst trade run up target opinion: $.4.40. Positive data release: Gap to $7. 1 year: $15 (my opinions only) According to company press releases, conference calls, and my correspondence with…
Weekend Update: $CORT $ATHX $CLSN $BLRX $NEPT + Chart Analysis And Explanation
In this video, I review a couple of charts, and review a couple of my trade calls. Chart analysis and explanation offered. Hope you find the video educational! Scott
Trade and buy Alert, Bought $CORT at 2.00, target opinion per chart = $2.50 short term.
Trade and buy Alert, Bought $CORT at $2.00, target opinion per chart = $2.50 short term. Pinched chart making a bounce back, minimal resistance til $2.50
